News Semaglutide scores again, this time in heart failure The list of benefits for Novo Nordisk's semaglutide keeps getting longer.
News Novartis pulls plug on landmark UK cholesterol trial ORION-17 study has been abandoned, with Novartis opting instead for a smaller global trial.
News FDA rejects Cytokinetics’ heart failure drug Firm will request a meeting with FDA, but may have to switch focus to folow-up drug aficamten.
News Abbott survey finds digital divide for patients, physicians Abbott's third report highlights disparities in digital health tool perceptions linger still.
R&D JP Morgan 2023 – Claudia Ulbrich Last month, pharmaphorum sat down with Claudia Ulbrich, CEO of Germany-based Cardior.
News NewAmsterdam's CETP renaissance gathers pace NewAmsterdam Pharma's bold play to resurrect an all-but defunct cholesterol-lowering drug class has been rewarded with a positive phase 2 trial of its oral CETP inhibitor obicetrapib.
